Description: Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Home Page: www.pumabiotechnology.com
PBYI Technical Analysis
10880 Wilshire Boulevard
Los Angeles,
CA
90024
United States
Phone:
424 248 6500
Officers
| Name | Title |
|---|---|
| Mr. Alan H. Auerbach | Founder, Chairman, Pres, CEO & Sec. |
| Mr. Maximo F. Nougues | CFO & Principal Accounting Officer |
| Dr. Alvin F. Wong Pharm.d. | Chief Scientific Officer |
| Mr. Douglas Hunt B.Sc., FRAPS | Sr. VP of Regulatory Affairs, Medical Writing & Project Management |
| Mr. Jeffrey Jerome Ludwig | Chief Commercial Officer |
| Mr. Mariann Ohanesian | Sr. Director of Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 11.2867 |
|---|---|
| Trailing PE: | 18.3077 |
| Price-to-Book MRQ: | 9.0642 |
| Price-to-Sales TTM: | 1.0452 |
| IPO Date: | 2012-04-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 196 |